EUCTR2008-000358-11-DEActive, not recruitingPhase 1
An open-label, multi-center, single-arm study to evaluate the efficacy of nilotinib in adult patients with metastatic or unresectable gastrointestinal stromal tumors in first line treatment
ovartis Pharma GmbH0 sites40 target enrollmentStarted: April 28, 2008Last updated:
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
Inclusion Criteria
- •Age =18 years
- •Histologically confirmed diagnosis of GIST that is unresectable and/or metastatic and therefore not amenable to surgery or combined modality with curative intent prior to or at Visit 1
- •At least one measurable site of disease on CT/MRI scan at Visit 1, as defined by RECIST criteria (see Post Text Suppl 3 for details) The scans should be at maximum 2 weeks old. New scans are only required as baseline scans if they are older then approx. 2 weeks.
- •WHO Performance Status of 0, 1 or 2
- •Patients must have the following laboratory values (= LLN (lower limit of normal) or corrected to within normal limits with supplements prior to the first dose of study medication.):
- •1.Potassium = LLN,
- •2.Magnesium = LLN,
- •3.Phosphorus = LLN,
- •4.Total calcium (corrected for serum albumin) = LLN
- •Patients must have normal organ, electrolyte, and marrow function as defined below:
- •1.Absolute Neutrophil Count (ANC) = 1.5x 109/L;
- •2.Platelets = 100 x 109/L;
- •3.ALT and AST = 2.5 x upper limit of normal (ULN) or = 5.0 x ULN if considered due to tumor;
- •4.Alkaline phosphatase = 2.5 x ULN unless considered due to tumor;
- •5.Serum bilirubin = 1.5 x ULN;
- •6.Serum lipase and amylase = 1.5 x ULN;
- •7.Serum creatinine = 1.5 x ULN or 24-hour creatinine clearance = 50 ml/min. (calculated creatinine clearance using Cockroft formula is acceptable)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Prior treatment with nilotinib
- •Treatment with any cytotoxic and/or investigational cytotoxic drug = 4 weeks (6 weeks for nitrosurea or mitomycin C) prior to Visit 1 with the exception of imatinib targeted therapy as an adjuvant therapy or imatinib in first line treatment for a maximum of 4 weeks
- •Prior or concomitant malignancies requiring active treatment other than GIST with the exception of previous or concomitant basal cell skin cancer, previous cervical carcinoma in situ
- •Impaired cardiac function at including any one of the following:
- •1.LVEF < 45% or below the institutional LLN range (whichever is higher) as determined by echocardiogram at Visit 1
- •2.Complete left bundle branch block
- •3.Use of a ventricular paced cardiac pacemaker
- •4.Congenital long QT syndrome or family history of long QT syndrome
- •5.History of or presence of significant ventricular or atrial tachyarrhythmias
- •6.Clinically significant resting bradycardia (< 50 beats per minute)
- •7.QTc > 450 msec on screening ECG (using the QTcF formula). If QTc > 450 msec and electrolytes are not within normal ranges (electrolytes should be corrected and then the patient rescreened for QTc.
- •8.Right bundle branch block plus left anterior hemiblock, bifascicular block
- •9.Myocardial infarction within 12 months prior to Visit 1
- •10.Other clinically significant heart disease (e.g., unstable angina, congestive heart failure or uncontrolled hypertension,)
- •Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol e.g. impairment of gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of the study drugs, uncontrolled diabetes
- •Use of therapeutic coumarin derivatives (i.e. warfarin, acenoucumarol, phenprocoumon)
- •Use of any medications that prolong the QT interval and CYP3A4 inhibitors if the treatment cannot be either safely discontinued or switched to a different medication prior to starting study drug administration. Please see http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm for a comprehensive list of agents that prolong the QT interval as well as Post-Text Supplement 2.
- •Patients who have undergone major surgery = 2 weeks prior to Visit 1 or who have not recovered from side effects of such surgery
- •Patients who have received wide field radiotherapy = 4 weeks or limited field radiation for palliation < 2 weeks prior to Visit 1 or who have not recovered from side effects of such therapy
- •A history of noncompliance to medical regimens or inability or unwillingness to return for scheduled visits
- •Patients who are pregnant, breast feeding or women of childbearing potential (WOCBP). Post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential Women of reproductive potential ,to include female partners of heterosexual or bisexual patients, must agree to use an effective method of contraception during the study and for up to three months following termination of the study.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
An open-label, multi-center, single-arm study to evaluate the efficacy of nilotinib in adult patients with metastatic or unresectable gastrointestinal stromal tumors in first line treatment - NDEUCTR2008-000358-11-ITOVARTIS FARMA40
Active, not recruiting
Not Applicable
An open-label, multi-center, single-arm study to evaluate the efficacy of nilotinib in adult patients with metastatic or unresectable gastrointestinal stromal tumors in first line treatmentEUCTR2008-000358-11-FIovartis Pharma Services AG
Active, not recruiting
Not Applicable
An open-label, multi-center, single-arm study to evaluate the efficacy of nilotinib in adult patients with metastatic or unresectable gastrointestinal stromal tumors in first line treatment.metastatic or unresectable gastrointestinal stromal tumorMedDRA version: 9.1Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorEUCTR2008-000358-11-FRovartis Pharma GmbH40
Active, not recruiting
Phase 1
Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients with Non-Hodgkin’s Lymphoma and Acute LeukemiaHyperuricemiaEUCTR2021-003176-14-Outside-EU/EEASanofi-Aventis Groupe
Active, not recruiting
Not Applicable
Open-label trial to evaluate the reduction in nonpsychotic behavioral side effects in patients who switched to brivaracetam treatment afterdiscontinuing levetiracetam due to nonpsychotic behavioral side effects.onpyschotic Behavioural Side Effects in Subjects With EpilepsyMedDRA version: 14.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-005177-23-ITCB PHARMA SA/NV.110